エピソード

  • ICT Ep13: Q2'24 The quarterly recap with Joel White (Part 3 of 3)
    2024/09/08

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's session we chat with Joel White from Marketcap Consulting about the financial performance of the clinical development space. In the final part of our 3 part discussion we talk through book to bill ratios, find out what is concerning Joel with the market and dive deeper into the Walgreens and BARDA agreement.

    続きを読む 一部表示
    18 分
  • ICT Ep13: Q2'24 The quarterly recap with Joel White (Part 2 of 3)
    2024/09/08

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In this session we continue our discussion with Joel White from Marketcap Consulting about the financial performance of the clinical development space. We find out what Joel is bullish about and dive into the pre-clinical space.

    Stay tuned for part 3.

    続きを読む 一部表示
    16 分
  • ICT Ep13: Q2'24 The quarterly recap with Joel White (Part 1 of 3)
    2024/09/08

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's session we chat with Joel White from Marketcap Consulting about the financial performance of the clinical development space. We discuss Joel's start in the industry, his thoughts on the macro trends and some of the challenges with technology.

    Stay tuned for part 2 and 3.



    続きを読む 一部表示
    15 分
  • ICT Ep12: How to Spot a Great Clinical Trial Site?
    2024/08/27

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's episode Ted and Liam discuss how do you spot a great clinical trial site? The question is much more complex than it first appears.

    Tune in to find out their thoughts on this.

    続きを読む 一部表示
    12 分
  • ICT Ep11: Effective Leadership in Clinical Trial Delivery
    2024/08/27

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's episode Liam and Ted discuss effective leadership in delivering clinical trials. What strategies and tactics have worked in the past?

    Tune in to find out

    続きを読む 一部表示
    14 分
  • ICT Ep10: Don't mistake the map for the territory
    2024/08/27

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    Liam delves into the critical concept of "Don’t Mistake the Map for the Territory" in the realm of clinical trial delivery. This metaphor highlights the importance of distinguishing between our plans and models—the 'map'—and the actual execution and outcomes—the 'territory.' In clinical trial delivery, it’s essential to recognize that no matter how well planned a trial is on paper, real-world challenges can impact results.

    Join us as we discuss how understanding this distinction can lead to more effective trial delivery and better outcomes for patients.

    続きを読む 一部表示
    12 分
  • ICT Ep9: What are the consequences of poorly designed protocols?
    2024/08/27

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's episode, Liam asks Ted the question 'what are the consequences of poorly designed protocols?'.

    Tune in to hear the discussion.

    続きを読む 一部表示
    12 分
  • ICT Ep8: Recruitment isn't Enrollment
    2024/08/01

    Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

    In today's episode, Liam and Ted discuss the idea that recruitment isn't the same as enrollment.

    Recruitment activities seem to focus more on outreach marketing campaigns that aims to attract attention. These marketing campaigns raise awareness in patient groups or healthcare providers. They are often accompanied by things such as website landing pages.

    In contrast, enrollment is a holistic (and complex) process. It focuses on activities leading up to a patient randomising into a trial. These activities aim to reduce barriers for both patients and sites. Increase access to the study.

    続きを読む 一部表示
    11 分